1. Most Discussed
  2. Gainers & Losers
NRT 0.0¢

Novogen - More Progress

  1. munch

    3,567 posts.

    ASX Code: NRT
    Announcement: Marshall Edwards & NIDCR join forces to study Phenoxodiol

    Date: 24 July 2002 - 14:37:55
    Market Sensitive: No

    NOVOGEN LIMITED 2002-07-24 ASX-SIGNAL-G

    HOMEX - Sydney

    +++++++++++++++++++++++++
    MEDIA RELEASE

    Novogen's listed subsidiary, Marshall Edwards Inc (AIM:MSH), has
    signed a Materials Cooperative Research and Development Agreement
    with the National Institute of Dental and Craniofacial Research
    (NIDCR), an Agency of the National Institutes of Health in the USA.

    The NIDCR is actively involved in research on novel therapies to
    treat oral, as well as head and neck, cancers. The agreement with the
    NIDCR is part of an international collaboration to further define the
    clinical applications of phenoxodiol.

    Phenoxodiol is under development as a primary anti-cancer therapy for
    a broad range of human cancers and is currently being tested in
    clinical trials in patients with advanced cancers in American and
    Australian hospitals.

    Phenoxodiol is the first anti-cancer drug licensed by Marshall
    Edwards Inc from Novogen Limited. This drug stems from the research
    program established by Novogen that has identified a family of
    compounds with novel anti-cancer actions. Marshall Edwards Inc has
    an option on all other Novogen anti-cancer compounds.

    Dr Graham Kelly, Chairman of Marshall Edwards Inc said "In addition
    to phenoxodiol, Novogen has identified a number of similar compounds
    that are showing selective activity against a number of common human
    cancers.

    "The action of these drugs against targets so fundamental to cancer
    cell survival suggests that they can kill cancer cells independent of
    the type of mutation behind the cancer and independent of their
    development of resistance to other drugs."

    Marshall Edwards Inc (AIM:MSH) was listed on the London Stock
    Exchange's Alternative Investment Market in May 2002.

    For further information:

    Professor Alan Husband
    RESEARCH DIRECTOR

    Dr Graham Kelly
    PHENOXODIOL PROGRAM DIRECTOR
    Novogen Limited

    TEL (02) 9878 0088
    http://www.novogen.com


DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top